WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List
12/15/2022 - 07:44 PM
SHANGHAI Dec. 15, 2022 Shanghai ) Co., Ltd. has been removed from the Unverified List (UVL) by the U.S. Department of Commerce, effective Dec. 16, 2022 . Consequently, both subsidiaries WuXi Biologics Co., Ltd. and WuXi Biologics (Shanghai ) Co., Ltd. have been successfully removed from the UVL.
In February 2022 , two subsidiaries of WuXi Biologics – WuXi Biologics Co., Ltd. and WuXi Biologics (Shanghai ) Co., Ltd. – were placed on the UVL due to delayed verifications required for the receipt of certain products exported from the United States . Subsequently, both subsidiaries successfully completed the on-site end-use checks conducted by the U.S. Department of Commerce, in coordination with China's Ministry of Commerce (MOFCOM). WuXi Biologics Co., Ltd. was removed from the UVL on Oct. 7, 2022 .
WuXi Biologics is committed to operating with the highest standard of compliance and in accordance with relevant laws and regulations.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
MediaPR@wuxibiologics.com
Businessinfo@wuxibiologics.com
https://www.prnewswire.com/news-releases/wuxi-biologics-shanghai-co-ltd-removed-from-the-us-commerce-departments-unverified-list-301704805.html
SOURCE WuXi Biologics
Wuxi Biologics (Cayman) Inc.
WXXWY Rankings
N/A Ranked by Stock Gains
WXXWY Stock Data
Industry
Testing Laboratories
Sector
Professional, Scientific, and Technical Services
Tags
Biotechnology, Health Technology, Professional, Scientific, and Technical Services, Testing Laboratories
Country
China (Mainland)
City
No 108 Meiliang Road Mashan
About WXXWY
wuxi biologics provides an open-access, integrated technology platform for biologics drug development. we are the only true service platform in the world offering end-to-end solutions to empower anyone to discover, develop and manufacture biologics from concept to commercial manufacturing. our single-source approach to biologics development saves our clients critical time and money. see below how our experience, capacities and quality make us a world leading (cdmo). experience wuxi biologics’ leadership team consists of industry experts with 15-20 years of experience in biological drug development in the u.s./eu. while at wuxi this team has contributed to 1 bla and 66 worldwide inds in just 3 years! expertise wuxi biologics has over 170+ returnees from large pharma and small biotechs in the u.s./eu. these scientists cover all facets of drug development from discovery to manufacture of final drug product. capacity and capabilities we have strong technical capabilities and an open-access
